Group 1 - Newnow (300765.SZ) reported its Q3 2025 results, with 18 institutional investors holding a total of 1.144 billion shares, representing 81.42% of the total share capital [1] - The top ten institutional investors collectively hold 81.17% of the shares, with a decrease of 0.47 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 10 funds increased their holdings, including Huatai-PineBridge Innovation Medicine Mixed A and ICBC Frontier Medical Stock A, with an increase rate of 0.60% [2] - Three public funds reduced their holdings, including China Europe Medical Health Mixed A, with a decrease rate of 0.37% [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.23% [2]

Core Insights - The A-share market has shown a "slow bull" trend in the first three quarters of this year, with significant contributions from the TMT sector, particularly in AI, robotics, and semiconductors [1] - Active equity fund managers have performed well, but the volatility in popular sectors and events like the "tariff shock" in early April have impacted their ability to manage drawdowns [1] - The average return for active equity fund managers this year is 34.08%, with a median return of 30.45%, while the average drawdown is -13.93% and the median drawdown is -13.05% [1][3] Fund Manager Performance by Management Scale Over 100 Billion - Among the 80 active equity fund managers with over 100 billion in management scale, the median return is 36.79% and the median drawdown is -14.13% [3] - Notable fund managers include Zhang Wei from Huatai-PineBridge and Ge Lan from China Europe Fund, both heavily invested in the pharmaceutical sector [3][4] 50-100 Billion - In the 50-100 billion category, 130 fund managers have a median return of 35.28% and a median drawdown of -13.28% [8] - The top performer is Zheng Ning from Bank of China Fund, achieving a return of 95.01% with a maximum drawdown of -13.06% [9] 20-50 Billion - For managers with 20-50 billion in assets, the median return is 32.82% and the median drawdown is -13.08% [10] - The top three fund managers include Dan Lin from Yongying Fund, Jin Xiaofei from Penghua Fund, and Zhao Longlong from Morgan Fund [12] Below 20 Billion - In the category of managers with less than 20 billion, the median return is 29.46% and the median drawdown is -12.95% [15] - The top three fund managers are Wang Chao from Fortune Fund, Qi Zhen from Huabao Fund, and Liu Haixiao from Haifutong Fund [15]

Core Viewpoint - The AI Fund Zhongyin Innovation Medical Mixed A (007718) reported a profit of 1.055 billion yuan for the first half of 2025, with a weighted average profit per fund share of 0.7264 yuan, and a net asset value growth rate of 54.08% [2] Fund Performance - As of September 2, 2025, the fund's unit net value was 2.418 yuan, with a recent three-month net value growth rate of 36.41%, ranking 12 out of 138 comparable funds [5] - The fund's six-month net value growth rate was 73.73%, ranking 8 out of 138, and the one-year growth rate was 105.10%, ranking 7 out of 135 [5] - Over the past three years, the fund's net value growth rate was 83.83%, ranking 2 out of 108 [5] Fund Management Insights - The fund manager, Zheng Ning, oversees four funds, all of which have positive returns over the past year [2] - The fund's management anticipates a moderate economic slowdown in the U.S. with a potential rise in inflation, influenced by tax cuts and regulatory relaxations under uncertain Trump policies [2] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 71.41 times, compared to the industry average of 120.96 times [10] - The weighted average price-to-book (P/B) ratio was about 5.97 times, while the industry average was 4.07 times [10] - The weighted average price-to-sales (P/S) ratio was approximately 10.65 times, against an industry average of 6.52 times [10] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.11%, and the weighted average net profit growth rate was 29.65% [17] - The weighted annualized return on equity was 0.08% [17] Risk and Return Metrics - As of June 30, 2025, the fund's Sharpe ratio over the past three years was 0.6073, ranking 4 out of 105 comparable funds [25] - The maximum drawdown over the past three years was 40.72%, with the largest quarterly drawdown occurring in Q1 2024 at 27% [27] Fund Composition - As of June 30, 2025, the fund had a total scale of 1.266 billion yuan, with 24,000 holders collectively owning 683 million shares [32][35] - The fund's turnover rate over the last six months was approximately 88.46%, consistently below the industry average for two years [38] - The fund's top ten holdings have consistently exceeded 60% concentration over the past two years, with major stocks including Innovent Biologics, Kelun-Biotech, and Hengrui Medicine [41]

Core Viewpoint - The Zhongyin Innovation Medical Mixed A Fund (007718) has shown significant performance in recent months, with a notable year-to-date return of 86.41%, ranking 31 out of 3882 in its category [1]. Fund Performance - The latest net value of the fund is 2.2431 yuan, reflecting a decrease of 2.30% [1]. - Over the past month, the fund achieved a return of 2.96%, ranking 3737 out of 4049 [1]. - In the last six months, the fund's return was 77.59%, ranking 28 out of 3916 [1]. - Year-to-date, the fund's return stands at 86.41%, ranking 31 out of 3882 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 62.83%, with the following key positions: - Innovent Biologics: 8.33% - Kelun-Biotech: 8.15% - Hansoh Pharmaceutical: 8.08% - CanSino Biologics: 8.07% - New Horizon Health: 6.13% - Baillie Gifford: 5.99% - BeiGene: 5.97% - Hengrui Medicine: 4.15% - Rongchang Biologics: 4.05% - ConvaTec: 3.91% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a strong background in the investment field, having previously worked as a stock research manager at Taikang Asset Management and as a senior researcher at Zhonggeng Fund Management [2]. - Zheng joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.3161 yuan, reflecting a growth of 1.15% [1] - The fund has shown a one-month return of 6.31%, a six-month return of 87.27%, and a year-to-date return of 92.48%, ranking 2207 out of 3424, 17 out of 3319, and 21 out of 3301 respectively [1] Fund Holdings - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Baillie Gifford (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1] Fund Manager Background - Zheng Ning, the fund manager of Zhongyin Innovation Medical Mixed A, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management, focusing on stock research in the healthcare sector [2] - Zheng Ning has been managing the fund since July 1, 2022, and has also taken on managerial roles for other healthcare-related funds [2]

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.1723 yuan, reflecting a decline of 3.54%. The fund has shown a one-month return of 12.66%, a six-month return of 78.76%, and a year-to-date return of 80.53% [1]. Fund Performance - The fund ranks 684 out of 4457 in the one-month category, 23 out of 4316 in the six-month category, and 29 out of 4287 in the year-to-date category [1]. Holdings Overview - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Bai Li Tianheng (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].

Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A Fund (007718) is 2.2349 CNY, reflecting a decline of 1.45% [1] - The fund has shown a one-month return of 20.54%, ranking 164 out of 4631 in its category; a six-month return of 88.98%, ranking 20 out of 4484; and a year-to-date return of 85.73%, ranking 27 out of 4447 [1] Fund Holdings - The top ten stock holdings of Zhongyin Innovation Medical Mixed A Fund account for a total of 62.83%, with the following allocations: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Hengrui Medicine (8.08%) - CanSino Biologics (8.07%) - Sinovac Biotech (6.13%) - Baillie Gifford (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino-B (3.91%) [1] Fund Manager Profile - Zheng Ning, the fund manager of Zhongyin Innovation Medical Mixed A Fund, has a background in finance with a master's degree and has held positions at various asset management companies, including as a stock research manager at Taikang Asset Management and a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A Fund since July 1, 2022, and has also taken on management roles for other funds within the company [2]

Core Viewpoint - The article emphasizes the importance of long-term value investing in the innovative pharmaceutical sector, highlighting the successful strategies employed by Zheng Ning, a fund manager at Zhongyin Fund, who has achieved significant returns by investing in innovative drugs during market downturns and focusing on long-term pricing rather than short-term fluctuations [1][2][3]. Group 1: Investment Strategy - Zheng Ning's investment approach is characterized by a focus on long-term pricing, filtering out short-term noise and market fluctuations, which distinguishes him from many growth stock fund managers [3][12]. - He has demonstrated a willingness to take contrarian positions, investing heavily in innovative drugs when the market was pessimistic and shifting focus to less popular sectors as the market evolves [3][4][30]. - The performance of his funds, such as Zhongyin Hong Kong Stock Connect Pharmaceutical Mixed A, which achieved an 84.18% return over the past year, reflects the effectiveness of his strategy [2]. Group 2: Market Insights - The innovative pharmaceutical sector is experiencing a collective explosion in growth, with significant revenue increases and profitability improvements among companies in this space [2][23]. - Zheng Ning believes that the current competitive landscape in China's innovative drug market is undergoing rapid changes due to policy shifts, which could lead to substantial opportunities for well-positioned companies [21][22]. - The article notes that the success of Chinese innovative drugs in international markets is a surprising development, with companies generating substantial overseas revenue [24]. Group 3: Risk Management - Zheng Ning emphasizes the importance of being responsible for every position held in the portfolio, focusing on risk-reward ratios rather than short-term performance rankings [4][29]. - He advocates for a balanced approach to investing, suggesting that maintaining a stable life outside of work can enhance investment performance [57]. - The article highlights the need for investors to be cautious at market peaks and to recognize when to take profits, contrasting this with the opportunities available at market bottoms [36][50]. Group 4: Future Outlook - Looking ahead, Zheng Ning is optimistic about the continued growth of the innovative pharmaceutical sector but is also exploring investment opportunities in domestic demand sectors that are currently undervalued [45][46]. - He anticipates that as the market matures, the investment landscape will shift towards higher risk and lower win rates, similar to trends observed in the U.S. market [22][24]. - The article concludes with Zheng Ning's assertion that he is not solely an innovative drug fund manager but rather a broader pharmaceutical industry manager, indicating potential shifts in his investment focus as market conditions change [48][49].

Group 1 - The core point of the article highlights the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown significant returns over various time frames, including a 76.52% return year-to-date [1] - The fund's recent net value is reported at 2.1241 yuan, with a slight decline of 0.96% [1] - The fund's performance rankings are notable, with a 13.58% return over the past month (ranked 488 out of 4001), an 80.76% return over the past six months (ranked 25 out of 3880), and a 76.52% return year-to-date (ranked 26 out of 3861) [1] Group 2 - The top ten stock holdings of the Zhongyin Innovation Medical Mixed A fund account for a total of 62.83%, with significant positions in companies such as Innovent Biologics (8.33%), Kelun-Biotech (8.15%), and Hengrui Medicine (8.08%) [1] - The fund was established on November 13, 2019, and as of June 30, 2025, it has a total scale of 1.266 billion yuan [1] - The fund manager, Zheng Ning, has a background in stock research and has held various positions in asset management companies before joining Zhongyin Fund Management in 2022 [2]

Core Viewpoint - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission marks the beginning of a full lifecycle policy support phase for China's innovative drug industry, accelerating its development [1] Group 1: Policy Support and Industry Development - The new policy includes 16 specific measures aimed at supporting innovative drug development across various dimensions such as research and development, medical insurance access, and clinical application [1] - Since the mention of "innovative drugs" in the 2024 Government Work Report, a series of supportive policies have been released, covering financing, drug approval, pricing, and insurance payment [1] - Systematic support is expected to help domestic pharmaceutical companies transition from a combination of imitation and innovation to global original research and development [1] Group 2: Market Performance and Investment Opportunities - The Hong Kong Stock Market's Hang Seng Innovative Drug Index has seen a year-to-date increase of 68.71% as of July 9, 2025, with a current TTM price-to-earnings ratio of 29.44, indicating potential for valuation recovery [2] - In 2024, Hong Kong innovative drug companies achieved revenue of 48.53 billion yuan, a year-on-year growth of 17.3%, with several leading firms turning profitable in 2025 [2] - The total amount of overseas licensing transactions by Chinese innovative drug companies reached 45.5 billion USD from January to May 2025, surpassing the total for the first half of 2024, validating the "research in China, monetization globally" business model [2] Group 3: Fund Performance - The Zhongyin Hong Kong Stock Connect Medical Mixed Fund has performed well, ranking 1st out of 41 similar products over the past year [2] - Zhongyin Innovation Medical Mixed A Fund has also shown strong performance, ranking 3rd out of 83 similar funds over the past year [3] - The overall market capitalization of the innovative drug sector is approximately 3 trillion yuan, presenting a favorable risk-reward ratio for investors [3]